Since its launch in 2008, sugammadex has been considered one of the most significant developments in anaesthesia-related pharmacology. With almost 500 sugammadex-related publications and over nine million patient exposures worldwide, user experience and scientific data have grown exponentially. However, several important questions are yet to be answered. This article reviews the sugammadex-related literature in 2013 and 2014 to determine which of these questions have been answered more fully over the last 18 months and which questions require more information and research.
Since sugammadex's regulatory approval in Australia in November 2008, almost 300,000 patients have received the drug Australia wide. According to MSD Australia, over nine million patients have received sugammadex worldwide. The introduction of sugammadex to antagonise non-depolarising neuromuscular blockade (NMB) has led to significant changes in anaesthesia practice [1] [2] [3] , with an increase in amino-steroidal neuromuscular blocking agent (NMBA) use and use of deeper intraoperative neuromuscular blockade until the conclusion of surgery. The superiority of sugammadex (versus neostigmine) for reversing neuromuscular block has now been well established. In fact, Della Rocca et al 4 have warned that, in the context of residual neuromuscular block-related incidents, hospitals are increasingly likely to face questions or complaints if sugammadex was unavailable or not used. Nevertheless, even after ten review articles [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] in the last 18 months, anaesthetists still search to find definite answers to basic questions about the optimal use of sugammadex and its place in their practice.
The aim of this review is to investigate what questions have been answered more fully over the last 18 months and what questions require more information and research.
Methods
All articles found in PubMed using the search term "sugammadex" (n=143; July 2014; filter: publication date 1.1.2013 to 31.7.2014) were investigated for inclusion in this literature review. The retrieved publications were then further categorised into subtopic-related questions to reflect where specifically they may contribute to new knowledge. Articles describing the already known pharmacology of sugammadex, review articles, letters to the editor or published comments not adding any new information were excluded from further analysis. Studies published prior to 2013 were cited only if crucially required in the context of newer investigations.
The results are presented under clinical question headings. The assessments of the various studies' strengths and flaws are presented first, followed by a summary pertaining to the clinical question in italics. Readers searching for briefer answers may choose to go straight to the summary for each clinical question.
Is sugammadex more rapid and more reliable in reversing residual neuromuscular block than neostigmine? Della Rocca et al 14 reported a non-randomised, prospective multi-site study involving 359 patients (207 sugammadex, 150 neostigmine). Patients had either a deep neuromuscular block (post-tetanic count 1 to 2: sugammadex n=44, neostigmine n=8) or a shallow block (reappearance of T2 in train of four [TOF]: sugammadex n=163, neostigmine n=142). Sugammadex reversal was found to be significantly faster than reversal with neostigmine (shallow block: 2.2 versus 6.9 minutes, deep block: 2.7 versus 16.2 minutes, P <0.0001). The authors also reported more patients with a TOF ratio <0.9 at 5, 10 or 20 minutes after reversal administration in the neostigmine group. Though the strength of this study might be its 'real-life' character, it was neither randomised nor blinded. Furthermore, the study did not prescribe a specific dose of each reversal agent and the authors had to admit that many patients received an incorrect dose of the reversal agent 14 .
A randomised and partially blinded study in 128 patients comparing neostigmine with sugammadex-based reversal was reported by Woo et al 15 . The primary outcome was the time from the reappearance of T2 to complete reversal in Korean (versus Caucasian, data previously published) patients. The latter was found to be 8.1 times faster (mean 1.8 versus 14.8 minutes, P <0.0001) in sugammadex-reversed versus neostigmine-reversed subjects. Four patients in the neostigmine group and none in the sugammadex group had adverse postoperative events possibly related to residual neuromuscular blockade (RNMB) 15 .
Ledowski et al 16 reported a prospective audit in 146 patients (53 no reversal, 57 sugammadex, 33 neostigmine), which found significantly more patients with TOF ratios <0.7 and <0.9 in the no-reversal and neostigmine versus the sugammadex group (<0.7: 20.9% versus 25% versus 0%; <0.9: 53% versus 59% versus 8%, P <0.0005). They also found a higher incidence of pathological chest X-ray findings in patients with TOF ratios <0.9 at the time of extubation. However, similar to the study by Della Rocca et al 14 , this audit was non-randomised, non-blinded and of purely observational character.
A further study investigating the rate of RNMB at the end of surgery was reported by Von Quillfeldt et al 17 , who describe a smaller observational comparison between 17 patients with a rocuronium/sugammadex combination versus 22 subjects with mivacurium/no reversal. Though surgeons (eye surgery) were 100% satisfied with the operating conditions in both groups, RNMB was frequently observed in the "no reversal", but not the sugammadex group. However, it appears that anaesthetists in this study elected to extubate even when the effect of mivacurium hadn't worn off completely (times from end of surgery to extubation were not different between groups). Hence, though the authors describe reversal with sugammadex as an "additional safety dimension" 17 , simply waiting longer until extubation in the mivacurium group might have prevented RNMB as well within a (hypothetically) reasonable time frame. This study may thus be best suited to underline the importance of neuromuscular monitoring.
In summary, sugammadex was found to reverse NMB approximately three to eight times faster than neostigmine 14, 15 . Deeper levels of NMB resulted in more advantageous reversal times for sugammadex 14 . The incidence of postoperative RNMB with TOF ratios <0.9 or <0.7 was significantly lower in sugammadex-versus neostigmine-or non-reversed (timing) patients 14, 16, 17 . A significant correlation between RNMB and postoperative chest X-ray pathology was reported in one investigation 16 .
Does sugammadex change the postoperative outcome of patients?
Two studies investigated "pulmonary outcome" after sugammadex versus neostigmine or no reversal 18, 19 . Llaurado et al 19 described a case series of 160 obese patients undergoing bariatric surgery who were reversed with sugammadex. They compared this group with a historical (matched) cohort of 160 patients reversed with neostigmine. After neostigmine reversal, the authors reported a significantly higher number of patients requiring postoperative ventilation (five versus two patients), as well as a significantly higher number of subjects with pathological postoperative X-ray findings (26 versus 11 patients). However, the study was neither randomised and blinded nor fully prospective. Ledowski et al 18 reported a retrospective investigation involving 1444 consecutive patients who received intraoperative NMBA and were either reversed with sugammadex (n=722) or non-sugammadex (n=722: 212 neostigmine, 510 no reversal). In this study, neostigmine reversal resulted in a higher rate of postoperative nausea and vomiting (PONV) in the post-anaesthesia care unit (PACU) (21.5% versus 13.6% after sugammadex). Furthermore, a significant influence of patient age on pulmonary outcome (assessed via an outcome score) was described. The latter influence was significantly less apparent after sugammadex versus neostigmine or no reversal administration in patients with an American Society of Anesthesiologists physical status score of 3 or 4 over the age of 60 years. Though this study suggests a better pulmonary outcome in sicker and older patients after reversal with sugammadex, the study was non-randomised and of retrospective character.
"Outcome" in sugammadex versus neostigmine trials has conventionally been defined as either speed/reliability of NMBA reversal or the incidence of pulmonary complications. Hence, a study by Castro et al 20 using postoperative pain as the primary outcome parameter may be interestingly different. The authors randomised 88 obese patients scheduled for laparoscopic bariatric surgery to receive either sugammadex or neostigmine at the end of surgery. Acute pain was rated on a visual analog scale at four timepoints in PACU (upon admission, at 30 and 60 minutes and at discharge). Sugammadex-reversed patients had significantly lower pain scores at 30 and 60 minutes post surgery (at 60 minutes, visual analog scale 4 to 7: n=2 in sugammadex versus n=15 in neostigmine group, P <0.05), as well as a lower incidence of PONV (sugammadex n=3, neostigmine n=8). Though the authors state sugammadex to be an "indispensable drug in this type of surgery" 20 , it remains unclear how the administration of sugammadex might have influenced postoperative pain scores and why such differences were found at 30 and 60 minutes postoperatively, but not at PACU admission or discharge. The authors discuss the lower incidence of PONV as well as a lower gastrointestinal motility after sugammadex as a potential explanation.
In summary, in two retrospective studies, reversal with sugammadex resulted in a significantly lower incidence of postoperative pulmonary complications (bariatric patients 18 , American Society of Anesthesiologists physical status scores of 3 or 4, >60 years of age 18, 19 ) and PONV 19 . One prospective, randomised investigation also reported a lower incidence of PONV but also postoperative pain 20 .
Is sugammadex of benefit in cases of anaphylaxis to rocuronium?
There have been few publications on this topic over the past 18 months. All but one was a case report, thus there is insufficient information to provide a definite answer to this question. Three authors reported a positive effect (haemodynamic improvement) following sugammadex administration during rocuronium-induced anaphylaxis [21] [22] [23] . However, there was also one case of a patient in whom sugammadex was not associated with immediate haemodynamic improvement 24 . A potential inhibitory effect of sugammadex on pancreatic mast cells in rats has also been reported 25 .
In summary, the administration of sugammadex in suspected anaphylaxis to rocuronium appears to be frequently [21] [22] [23] , but not always 24 associated with haemodynamic improvement, but the mechanism of this improvement has yet to be clarified.
Is sugammadex of benefit in difficult airway or other emergency scenarios?
Many papers discuss the use of sugammadex in difficult airway/'can't intubate, can't ventilate' scenarios [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] . A further article investigated the effect of sugammadex on verapamil toxicity 38 . In the context of airway-related emergencies, few new aspects have been reported. Woloszczuk-Gebicka et al 37 reported a case of a successful rescue of the lost airway in a ten-month-old infant and Paton et al 34 reported one case in a 53-year-old male patient. There is no doubt that sugammadex is one strategy to rescue the lost airway in some cases, and the drug should ideally be kept on difficult airway trolleys. However, many letters to the editor [26] [27] [28] [29] in reply to the case report by Paton et al 34 , as well as an editorial by Mendonca 32 accompanying the publication of the same case report in Anaesthesia, have again made it clear that sugammadex should not be seen as the 'silver bullet' of difficult airway treatment and that it should not become an integral part of the difficult airway algorithm. Prior to reversal of muscle relaxation with sugammadex in a 'can't intubate, can't ventilate' scenario, it must specifically be clear whether a 'way back' realistically exists. Frequently, especially in the emergency department setting, only a forward strategy (i.e. surgical airway) can be safely applied 36 .
Ozbilgin et al 38 investigated the effect of sugammadex on verapamil intoxication in rats, as there is a known affinity for cyclodextrins to verapamil. They found the cardiotoxicity of verapamil to be delayed after 16 mg/kg, but accelerated after 1000 mg/kg and concluded that further investigations were required to investigate this drug interaction.
In summary, recent case reports have emphasised that the rapid return of neuromuscular function following sugammadex may be helpful in rescuing the lost airway, but it is clear that it is not the answer for all related scenarios and that alternative strategies (i.e. surgical airway) may be required.
Does sugammadex facilitate safe non-depolarising neuromuscular block in patients with comorbidities or co-medications in whom muscle paralysis would have formerly been considered dangerous?
Thirty-five references discuss the use of sugammadex in specific circumstances . As in previous years, the safe administration of sugammadex in patients with various comorbidities/special circumstances has been described in a multitude of case reports:
Aldosteroma 55 , amyotrophic lateral sclerosis 49, 66 , Brugada syndrome 42, 51 , Duchenne muscular dystrophy 73 , hepatectomy patients 56 , myasthenia gravis 54, 62 , congenital myotonic dystrophy type 1 58 , spinal muscular atrophy type 3 47 , myotonic dystrophy and spinal muscular atrophy 60 , a parturient with myotonic dystrophy 61 , paediatric oncology patients 53 , acute porphyria 64 , pseudocholinesterase enzyme deficiency 63 , severe cardiac failure 65 , Sjögren's syndrome 40 , Strumpell-Lorraine disease 43 and a patient with trisomy 8 mosaicism combined with cerebral palsy 69 .
Of note, two case reports noted that sugammadex might not always result in adequate extubation conditions in highrisk patients: Kiss et al 50 reported a case of therapy-resistant fade in the TOF despite the administration of 12 mg/kg sugammadex in a patient with myasthenia gravis and Kayashima et al 68 discussed a case of a woman with poor pulmonary function who could not be extubated at the end of surgery, despite sugammadex-based reversal. The latter reports underline the fact that neuromuscular monitoring remains imperative to check the effectiveness of RNMB reversal after every type of reversal agent and that patients with preoperative poor functional status may not only be impaired by RNMB but also other aspects of surgery/anaesthesia.
A randomised, double-blinded study by Czarnetzki et al 67 investigated the effect of magnesium (MgSO 4 60 mg/kg) pre-treatment versus a placebo in 32 patients. They concluded that the described dose of magnesium did not alter the efficacy of the recommended doses of sugammadex after moderate and deep block with rocuronium. Sakurai et al confirmed the latter results in a case series reported 70 when they investigated the effects of sugammadex reversal in 23 women undergoing caesarean delivery, some of whom had received magnesium pre-treatment.
Two articles discuss the use of sugammadex in the context of electroconvulsive therapy 44, 72 . Saricicek et al 72 found the incidence of post electroconvulsive therapy myalgia and headaches significantly reduced after sugammadex/ rocuronium versus succinylcholine administration. They also reported significantly shorter times to spontaneous ventilation and eye opening in the sugammadex/rocuronium group.
Finally, a case report by Lobaz et al 52 needs to be mentioned, as the authors describe a case of significantly delayed spontaneous recovery from rocuronium-induced paralysis in an elderly patient with severe renal failure. The patient failed to recover (persistent fade in TOF) 180 minutes post rocuronium administration and was successfully extubated five minutes after sugammadex administration. The case highlights the potential for sugammadex use in patients with renal failure, even though severe renal failure is named as a contraindication in the prescriber information for the drug. The latter is based on the renal excretion of the sugammadex-rocuronium (or vecuronium) complex and the potential dissociation of the complex in the case of non-excretion 74, 75 . Though sugammadex has been shown to be dialysable via high-flux dialysis 76 , the use of the drug in patients with severe renal failure should be very carefully considered and appropriate postoperative monitoring organised (day-case surgery cannot be recommended).
In summary, many case reports have found sugammadex to be safe for neuromuscular blockade reversal in the presence of significant comorbidities. Furthermore, sugammadex does not appear to be significantly influenced by the administration of magnesium and a rocuronium-sugammadex combination may provide benefits when anaesthetising electroconvulsive therapy patients. Though not routinely recommended, sugammadex may be used to reverse RNMB in critical scenarios, even in patients with severe renal failure. However, in this case a high vigilance for potential re-curarisation would have to be maintained.
What is the optimum dose of sugammadex and what recovery times can be expected?
Ten articles were published on the appropriate dose for sugammadex or its onset time 7, 67, [77] [78] [79] [80] [81] [82] [83] [84] . In this context, a double-blinded, randomised study by Pongracz et al 79 investigated 80 patients receiving sugammadex doses of 0.5, 1 and 2 mg/kg or neostigmine 0.05 mg/kg at the reappearance of four TOF twitches. The authors found that sugammadex 1 mg/kg rapidly and effectively reversed a shallow rocuronium-induced block and that even a dose of 0.5 mg/kg was effective, but the time to recovery was slower (up to eight minutes). In the accompanying editorial in Anesthesiology, Kopman 78 points out that the number of patients in each group was relatively small and recovery times were truncated at 15 minutes, resulting in a potentially over-optimistic result for the neostigmine group (full recovery of TOF within a mean of 8.5 minutes). However, neostigmine reversal still had the slowest onset (sugammadex 0.5 mg/kg: 4.1 minutes, sugammadex 1 mg/kg 2.1 minutes). In this context, it must be pointed out that even higher doses of sugammadex may occasionally be insufficient to fully antagonise RNMB. Kayashima et al 83 reported a case of insufficient recovery after sugammadex 2.3 mg/kg at a TOF count of 2 in an obese woman undergoing caesarean section. Furthermore, it is worth noting that the onset times quoted for sugammadex are frequently mean values with an often unreported, relatively wide range. The latter is specifically emphasised in a literature review of sugammadex onset times by Van Gestel and Cammu 82 . Quantitative neuromuscular monitoring is needed to confirm complete reversal of blockade.
Another hotly debated issue is the optimum dose of sugammadex in morbidly obese patients. After Van Lancker et al 85 (2011) quoted the ideal body weight (IBW) + 40% to be a safe weight for the dose calculation, Sanfilippo et al 80 concluded in 2013 that a dose calculation based on IBW only might also be safe. This conclusion was based on a relatively small study involving only 20 patients per group (IBW versus real body weight used to calculate the dose of sugammadex). Furthermore, the discussion specifically mentions the risk of incomplete reversal or re-curarisation 80 potentially arising from under-dosing of sugammadex. In a reply to the article by Sanfilippo et al, Carron 86 also pointed out that, on closer examination of the results, not all patients in whom the dose of sugammadex had been based on IBW had TOF ratios >0.9 at the time of extubation and that the time to TOF recovery had been slow in the IBW group. The discussion again underlines the need for quantitative neuromuscular monitoring even after the use of sugammadex. Without monitoring, RNMB rates of up to 9.4% have been described 87 .
In summary, lower than recommended (prescription information) doses have been used in both obese and non-obese patients. Though reversal of shallow RNMB may be possible with a low dose of sugammadex, the time to neuromuscular recovery may take longer or an additional dose may be required. Under-dosing of su-gammadex cannot be recommended. However, if lower than recommended doses are used, quantitative neuromuscular monitoring is mandatory.
What new information exists on the side-effects of sugammadex including anaphylaxis?
Five papers dealt with the problem of sugammadextriggered anaphylaxis [88] [89] [90] [91] [92] . A literature review of the issue by Tsur and Kalansky 92 in Anaesthesia in 2014 can be specifically recommended. Their comprehensive search of online databases, as well as in reports by regulatory agencies and MSD Australia, revealed a total of 15 probable cases of sugammadex anaphylaxis worldwide 92 . Fourteen of 15 events occurred within four minutes or less after sugammadex administration, prompting the authors to recommend specific vigilance during this period of time. Overall, hypersensitivity to sugammadex appears to remain a rare but serious event. In case of confirmed reactivity to sugammadex, a positive reaction in intradermal skin testing can usually be obtained with a 1:100 dilution 88, 89 and frequently also with a 1:1000 dilution of sugammadex 89 . Sadleir et al published a useful protocol for post-event skin testing 89 .
Four publications discussed the hypothetical risk of increased bleeding after sugammadex administration due to in vitro slight heparin-like effects [93] [94] [95] [96] . De Kam et al 94 found no clinically relevant interaction between aspirin and sugammadex in a randomised, double-blinded, controlled study on 26 male subjects. The same authors, however, detected a small (up to 22% after sugammadex 16 mg/kg), dose-dependent effect on the activated partial thromboplastin time in separate investigations involving eight healthy volunteers 95 . They also studied the interaction of enoxaparin treatment and sugammadex and reported no clinically meaningful increase of anti-Xa activity or activated partial thromboplastin time after 4 or 16 mg/kg sugammadex 96 . Carron 93 therefore concluded that sugammadex did not represent a bleeding risk in surgical patients.
Another unwanted event in a timely association with sugammadex administration was the development of negative pressure pulmonary oedema 100 . In this case, inspiratory forces created by the diaphragm may have overcome the patency of pharyngeal muscle function, despite a TOF recovery >0.9. In an in vitro experiment with innervated muscle cells, Rezonja et al 97 found a potential chemical interaction between dexamethasone and sugammadex. In a second experiment 98 , the same authors demonstrated a diminished effect of sugammadex by the concomitant administration of dexamethasone. Though the clinical relevance of these findings remains uncertain, administration of high-dose dexamethasone in close, timely association with reversal with sugammadex should prompt a high degree of caution. Palanca et al have described a further, yet unreported, potential side-effect of sugammadex administration 101 . The authors investigated the toxicity of sugammadex on primary nerve cell cultures in rats and found a sugammadex-induced activation of mitochondria-dependent apoptosis which was associated with a depletion of neuronal cholesterol levels. However, they also pointed out that the penetration of sugammadex via the blood-brain barrier was usually poor (<3%) and that higher penetration rates were only expected to be found under special circumstances such as immaturity or infections. Though both translation of the findings into human neuronal pathophysiology and their clinical relevance are certainly unclear, the results may suggest potentially severe consequences in cases of inadvertent intrathecal application of sugammadex.
One case of transient increase of the vecuronium plasma level has been described by Shimizu et al 75 in a young child with prolonged use of vecuronium in the intensive care setting. Although sugammadex administration in this case was found successful for reversing the neuromuscular block, the authors emphasised the potential risk of re-curarisation after long-term use of vecuronium. On a more positive note, sugammadex has been described as having no effect on the QTc in a review by Staikou et al 99 . Neostigmine-atropine in turn has been associated with significant prolongation in the QTc 99 .
In summary, anaphylaxis remains the most important potential side-effect of sugammadex administration. However, this appears to be an extremely rare event and in line with the frequency of anaphylaxis to other anaesthetic drugs [88] [89] [90] [91] [92] . Though a theoretical concern, no clinically significant influence of sugammadex on perioperative bleeding was identified [93] [94] [95] [96] . Other side-effects of the drug appear to be less severe and rare. A potential interaction between dexamethasone and sugammadex will need to be further assessed for its clinical relevance 97, 98 . Sugammadex does not appear to have an effect on the QTc 99 .
Are there other new findings of clinical interest related to sugammadex?
The antimicrobial effects of sugammadex were investigated by Hanci et al 102 in an in vitro experiment. Sugammadex was found to have no antimicrobial effect on S. aureus, E. faecalis, E.coli and Pseudomonas aeruginosa. The results prompted the warning by the authors to maintain sterile conditions when preparing sugammadex and to not use the same preparation of the drug for more than one patient.
In summary, no new risks of sugammadex have been identified.
Conclusion
Over the past 18 months, it has been reconfirmed that sugammadex acts more rapidly and is more reliable in reversing RNMB than neostigmine. This difference is more pronounced when a deep neuromuscular block is reversed.
Prospective, randomised and blinded trials are required to support or reject the hypothesis of a better postoperative outcome after sugammadex reversal. Such studies should ideally include data to investigate the cost/benefit ratio for the use of sugammadex.
Sugammadex may assist in the treatment of some patients with a suspected anaphylaxis to rocuronium, although the underlying mechanism is currently unclear. Further data are required to support or refute a role for sugammadex during rocuronium allergy and to identify which patients may specifically benefit from the (hypothetical) therapeutic effect of the drug.
Sugammadex promotes rapid return of muscle power in patients who have received NMBA, which may assist in the management of some, but not all, difficult airway scenarios. Therefore, while it belongs on the difficult airway trolley, alternative rescue strategies may be required.
Sugammadex should be dosed according to the prescriber information issued by the manufacturer. Large randomised controlled trials comparing the effects (i.e. onset times, reliability and risk of under-treated RNMB) of each dosage regimen are required before lower doses can be considered safe. If sugammadex is under-dosed, careful quantitative neuromuscular monitoring is essential and increased postoperative vigilance is required in order to identify the problems of incomplete reversal or re-curarisation.
Sugammadex has been shown to be safe in the presence of a plethora of comorbidities and co-medications. Magnesium is not likely to significantly alter the speed or reliability of RNMB reversal with sugammadex. Currently, there is no evidence for a sugammadex-induced increased risk of perioperative blood loss. No effect on the QTc has been reported. Though not generally recommended, sugammadex has been used in patients with severe renal failure. Sugammadex can be high-flux dialysed.
The side-effects of sugammadex administration are rare. Anaphylaxis is the most serious. It appears that the risk of anaphylaxis is not higher than that for other anaesthetic drugs, particularly muscle relaxants. However, further data on the true rate of anaphylaxis are required, especially in certain sub-populations. In addition, the potential interaction with dexamethasone and the reported small animal data on the neurotoxic effect warrants further investigation.
Finally, and most importantly, further educational work on quantitative neuromuscular function monitoring and upgrading the basic professional guidelines of monitoring is essential, even if sugammadex is used. Anaesthetists need to understand the crucial role of neuromuscular monitoring to ensure patient safety after the use of NMBA. Residual neuromuscular blockade remains a frequently underestimated but potentially dangerous condition. This cannot be fully mitigated by the administration of sugammadex alone in the absence of quantitative neuromuscular function monitoring.
Conflict of interest
Thomas Ledowski has consulted for, and accepted a research grant from, MSD. However, none of the aforementioned has been related to this publication, and MSD has not in any form been involved in the preparation of this manuscript.
